Proposed routine monitoring of the efficacy and tolerableness of treatment with interferon α in patients with chronic hepatitis C
| Treatment (month) | Post-treatment follow up (month) | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 | 11 | 12 | 14 | 16 | 18 | 21 | 24 | ||
| Efficacy | ||||||||||||||||||
| Clinical | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| ALT | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | X | |
| HCV RNA | X | X | X | |||||||||||||||
| Tolerableness | ||||||||||||||||||
| WBC and platelet count | X | X | X | X | X | X | X | X | X | X | X | X | ||||||
| TSH | X | X | X | X | X | |||||||||||||
WBC, white blood cell; TSH, thyroid stimulating hormone.